51146-56-6
51146-56-6 结构式
基本信息
S-布洛芬
(S)-(+)-布洛芬
右布洛芬
左旋布洛芬
(S)-(+)-布洛芬/2-(4-异丁基苯基)丙酸
d-Ibuprofen
DEXIBUPROFEN
(S)-IBUPROFEN
S(+)-IBUPROFENE
(S)-(+)-IBUPROFEN
(S)-(+)-Ibuprofen,99%
(S)-(+)-Ibuprofen, 98.5%
(S)-((addition))-Ibuprofen
(S)-(+)-Ibuprofen, 99% 1GR
s(+)-2-(4-isobutylphenyl)propionic
(+)-(S)-p-Isobutylhydratropic acid
S(+)-IBUPROFEN ACTIVE ISOMER OF IBUP
(S)-(+)-Ibuprofen ReagentPlus(R), 99%
(S)-2-(4-Isobutylphenyl)propanoic acid
(S)-2-(p-Isobutylphenyl)propionic acid
(S)-(+)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID
(S)-(+)-4-Isobutyl-α-methylphenylacetic acid
(S)-2-(4-Isobutylphenyl)propanoic acid, 95+%
(2s)-2-[4-(2-methylpropyl)phenyl]propionic acid
(S)-(+)-4-ISOBUTYL-ALPHA-METHYLPHENYLACETIC ACID
(aS)-a-Methyl-4-(2-methylpropyl)benzeneacetic Acid
Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-, (S)-
[αS,(+)]-α-Methyl-4-(2-methylpropyl)benzeneacetic acid
Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-, (αS)-
(S)-(+)-Ibuprofen (S)-(+)-4-Isobutyl-alpha-methylphenylacetic Acid
(S)-(+)-2-(4-Isobutylphenyl)propionic acid, (S)-(+)-4-Isobutyl-α-methylphenylacetic acid
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-78131A | S-布洛芬 (S)-(+)-Ibuprofen | 51146-56-6 | 500mg | 350元 |
| 2024/01/25 | HY-78131A | S-布洛芬 (S)-(+)-Ibuprofen | 51146-56-6 | 10mM * 1mLin DMSO | 385元 |
| 2024/01/25 | HY-78131A | S-布洛芬 (S)-(+)-Ibuprofen | 51146-56-6 | 1g | 450元 |
常见问题列表
|
COX-1 2.1 μM (IC 50 ) |
COX-2 1.6 μM (IC 50 ) |
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1.
(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.
(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC
50
of 61.7 μM.
Cell Proliferation Assay
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 700 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 8 days |
| Result: | Reduced concentration dependently cell survival in both cell lines to a similar extent. |
Cell Cycle Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 24 hours (HCT-15) or 20 hours (HCA-7) |
| Result: | Caused a G0/G1 phase block. |
Apoptosis Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 72 hours |
| Result: | Induced cell apoptosis. |
Western Blot Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 900 µM |
| Incubation Time: | 4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours |
| Result: | Decreased levels of Cyclin D1 protein. |
(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.
| Animal Model: | NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells |
| Dosage: | 15 mg/kg/day |
| Administration: | Intraperitoneal injection; five days a week; for 4 weeks |
| Result: | Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice. |